Boryung signs deal with Stendhal to launch hypertension drug in Mexico

Boryung, a South Korean pharmaceutical company, said on Monday it had signed a deal with Stendhal SA de CV, a Mexican medical specialty company, to launch its hypertension combination drug Dukarb Plus in Mexico this year.

Dukarb Plus is part of Boryung’s Kanarb Family product line, which consists of Kanarb, a new hypertension drug, and its combination drugs Kanarb Plus that add other hypertension treatment ingredients. Dukarb Plus combines Kanarb with a calcium channel blocker and a diuretic.

Boryung said it aimed to increase the market share of the Kanarb Family in Mexico and enter the public insurance market with Stendhal’s support.

The company also said it had presented the clinical effects and prescription cases of Kanarb products at the International Conference on Cardiovascular Intervention (CADECI) held in Mexico on Feb. 23.

“We will continue to strengthen cooperation with Stendhal and increase our market share in Mexico through expanding Kanarb’s lineup,” Boryung CEO Daniel Chang said in a statement.

Write to Ji-Hyun Lee at bluesky@hankyung.com